Filing Flows › BeOne Medicines (ONC) › Q2 2026
BeOne Medicines (ONC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
BeOne Medicines (ONC) reported revenue of $1.7B for the second quarter 2026 (Q2 2026), +30% from a year earlier and +13% from the quarter before. Operating margin was 19.1%, net earnings $237M (13.9% of revenue).
BeOne Medicines, Q2 2026: revenue $1.7B (+30% year over year), operating margin 19.1%, net earnings $237M, operating cash flow $463M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7B | +13% | +30% |
| Gross profit | $1.5B | +14% | +33% |
| Operating profit | $325M | +30% | +270% |
| Net earnings | $237M | +4% | +151% |
| Operating cash flow | $463M | +130% | +76% |
| Free cash flow | $435M | +171% | +98% |
What changed
Revenue was $1.7B in Q2 2026, up 30% year over year and up 13% from the previous quarter. BRUKINSA was the largest line at 73% of revenue. BRUKINSA added $0.30B year over year (up 31%), 76% of the total change. KYPROLIS declined 22%.
Gross margin was 89.8%, up 2.3 points from Q2 2025. Operating profit was $0.33B, a 19.1% margin (up 12.4 points year over year). Of the extra revenue versus Q2 2025, 61% reached operating profit, above the 7% margin then. Operating expenses grew 13% against revenue growth of 30%. The fastest-growing cost line was Research & development (+17%). Net earnings were $0.24B, up 151% year over year. The effective tax rate was 24.1%.
Operating cash flow was $0.46B (up 76% year over year), 195% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items added $0.05B. Capital expenditures of $0.03B left free cash flow of $0.44B.
Questions
What was BeOne Medicines' revenue in the second quarter 2026?
BeOne Medicines (ONC) reported revenue of $1.7B for the second quarter 2026 (Q2 2026), +30% from a year earlier and +13% from the quarter before.
Was BeOne Medicines profitable in the second quarter 2026?
Operating profit was $325M (19.1% of revenue) and net earnings $237M.
Source: BeOne Medicines 10-Q on SEC EDGAR.